# Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

> **NCT05096663** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 82 (actual)

## Conditions studied

- Advanced Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Stage III Lung Cancer AJCC v8
- Stage IIIA Lung Cancer AJCC v8
- Stage IIIB Lung Cancer AJCC v8
- Stage IIIC Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
- Stage IVA Lung Cancer AJCC v8
- Stage IVB Lung Cancer AJCC v8

## Interventions

- **DIETARY_SUPPLEMENT:** Cobalamin
- **DRUG:** Dexamethasone
- **DRUG:** Docetaxel
- **DIETARY_SUPPLEMENT:** Folic Acid
- **DRUG:** Gemcitabine
- **DRUG:** Nogapendekin Alfa
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Pemetrexed
- **BIOLOGICAL:** Ramucirumab

## Key facts

- **NCT ID:** NCT05096663
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-15
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05096663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05096663, "Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT05096663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*